Inhibitors of the BET bromodomain proteins are promising cancer therapeutics, but tumour cells are likely to become resistant to these drugs. Anticipated mechanisms of resistance have now been described. See Letter p.413
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting bromodomain-containing proteins: research advances of drug discovery
Molecular Biomedicine Open Access 05 May 2023
-
Regulation of programmed cell death by Brd4
Cell Death & Disease Open Access 20 December 2022
-
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4
Oncogenesis Open Access 12 March 2021
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Klijn, C. et al. Nature Biotechnol. 33, 306–312 (2015).
Lackner, M. R., Wilson, T. R. & Settleman, J. Future Oncol. 8, 999–1014 (2012).
Baylin, S. B. & Jones, P. A. Nature Rev. Cancer 11, 726–734 (2011).
Rathert, P. et al. Nature 525, 543–547 (2015).
Fong, C. Y. et al. Nature 525, 538–542 (2015).
Shu, S. et al. Nature 529, 413–417 (2016).
Eilers, M. & Eisenman, R. N. Genes Dev. 22, 2755–2766 (2008).
Qi, J. Cold Spring Harb. Perspect. Biol. 6, a018663 (2014).
Wang, Y. et al. Science 327, 1650–1653 (2010).
Singh, A. & Settleman, J. Oncogene 29, 4741–4751 (2010).
Author information
Authors and Affiliations
Corresponding author
Related links
Rights and permissions
About this article
Cite this article
Settleman, J. Bet on drug resistance. Nature 529, 289–290 (2016). https://doi.org/10.1038/nature16863
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature16863
